COMPANY:

OncoDNA

"OncoDNA in March will begin rolling out a new liquid biopsy assay in European and other markets for cancer therapy selection, early disease detection, and minimal residual disease monitoring."

''OncoDNA and KU Leuven...announce that the innovative GIPXplorePLUZ solution, developed within the scope of the ONCNGS European project, will soon be commercialised under the brand name OncoXPLORE®''

"MGI...today announced the collaboration with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The OncoDEEP® Kit’s comprehensive workflow— encompassing sequencing, secondary analysis, and final interpretation of NGS data (OncoKDMTM) —is now fully compatible with MGI sequencers."

"MGI Tech Co., Ltd....announced the collaboration with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The OncoDEEP® Kit’s comprehensive workflow—encompassing sequencing, secondary analysis, and final interpretation of NGS data (OncoKDM™) —is now fully compatible with MGI sequencers."

"OncoDNA...announced its support to the extension of the AURORA program, which aims to include 252 more patients. The extension will specifically focus on patients with Triple Negative Breast Cancer (TNBC), Invasive Lobular Carcinoma (ILC) and those with late relapses beyond 10 years of initial breast cancer diagnosis."

"OncoDNA...announced the next stage in its partnership with C2i Genomics...The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test."

"OncoDNA...announced its participation in the oncNGS tender. Together with IQVIA, we are challenged by the ONCNGS CONSORTIUM to come up with a solution for analysis in liquid biopsies which should represent the ‘best NGS test, for all solid and lymphoid tumors’."

"OncoDNA...and ELI LILLY ITALIA...are proud to announce their partnership to facilitate access to biomarker testing and support the selection of the best therapy for thyroid cancer patients in italy...The partnership between Lilly and OncoDNA provides next-generation sequencing (NGS) molecular testing for thyroid cancer on tumor tissue biopsy to individuate treatable cancer biomarkers, by the identification of several gene alterations leading to potentially eligible patients for targeted therapies."

"...this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP for the purpose of routine next generation sequencing."

"ONCODNA...ANNOUNCED THE OFFICIAL LAUNCH OF THE ONCODEEP KIT DURING THE ESMO (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) CONGRESS IN PARIS, FRANCE. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION TO ENABLE LABORATORIES WITH NGS CAPABILITIES TO SUPPORT ONCOLOGISTS IN FINDING THE MOST EFFECTIVE AND PERSONALIZED TREATMENTS FOR THEIR CANCER PATIENTS."

"OncoDNA...announced today a partnership with Synlab...integrating OncoDEEP in their portfolio, Synlab laboratories in Germany will perform comprehensive testing of solid tumors and deliver decision support for oncologists. The technology transfer is ongoing, with the objective of processing the first patient samples early Q2."

"OncoDNA...announced today the launch of the OncoDEEP kit. The kit offers a complete workflow solution which enables laboratories with NGS capabilities to perform comprehensive biomarker testing, provide powerful data analysis and support oncologists in the most effective and personalized treatments for their cancer patients. The OncoDEEP kit integrates both reagents and quality control standards for the sequencing of over 600 cancer biomarkers. the offer will come in combination with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. OncoDEEP kit is available for early access and will be commercially available by the end of Q2 2022."